[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)].
Yamaguchi
Takafumi
T
yamaguchi_takafumi@lilly.com
Uenaka
Kazunori
K
Imaoka
Takeshi
T
D001794:Blood Pressure / Q000187:drug effects; D002243:Carbolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism; D007172:Erectile Dysfunction / Q000188:drug therapy*; D018565:Food-Drug Interactions; D006801:Humans; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000378:metabolism; D010413:Penis / Q000098:blood supply / Q000378:metabolism; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D000068581:Tadalafil
D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D006152:Cyclic GMP